@AaronGerds is busy today - now presenting findings from that pacritinib is generally well tolerated in MF patients who failed or didn’t tolerate ruxolitinib - important implications for this population! #ASH19#MPN
@MikkaelSekeres reviewing what’s in the pipeline for lower risk MDS. Enjoyed the sailing analogy for newer therapies filling our sails like the wind and moving us forward in the treatment of this disease! (Luspatercept?!)💨⛵️⚓️ #ASH19#MDS#ILoveBoating
@NathanielRosko presenting research completed in collaboration with @HanjieRx when he was an oncology pharmacy resident discussing the safety of rapid infusion daratumumab. Important implications for patients and infusion centers! Great job! #ASH19#MYELOMA
When you feel like you have balcony seats for a play at the theater but it’s @MikkaelSekeres presenting on glasdegib + azacitidine in AML and MDS #ASH19. Possibly a great up and coming treatment option for patients!
So proud of @KellyBeanstalk for being selected for the 2018 trainee poster winner after her fantastic presentation on rapid rituximab in a pediatric population @HOPArx#hopa18 Congratulations on all your hard work!!
Great lung cancer presentation by Dr. Ross Camidge @HOPArx#HOPA18 - pseudoprogression present in 2-8% with PD-1 pathway agents. Somewhere between zebra and unicorn #oncopharm